A lack of up-to-date New Zealand research into common gut disorders means the country is effectively flying blind on conditions that may affect around one in three adults, University of Otago research suggests.
Dr Simone Bayer and research colleagues from the University of Otago have reviewed all available evidence in Aotearoa on disorders of gut-brain interaction (DGBI) – a group of chronic conditions including irritable bowel syndrome (IBS) and functional dyspepsia.

Dr Simone Bayer
Their findings reveal a striking lack of contemporary data on how common these conditions are, who is affected, and what costs they incur to our health system.
Only four New Zealand studies reporting the prevalence of DGBI were identified, with the most recent published in 2002. The studies were limited to Wellington and Dunedin, and none provided prevalence data for Māori or Pacific peoples.
“People living with these conditions can experience significant and ongoing symptoms, yet we don’t have any strong contemporary evidence telling us how many New Zealanders are affected,” Dr Bayer says.
“That means we are also unable to properly comprehend the scale of demand on our health system, or whether different groups of New Zealanders are experiencing these conditions and accessing care in different ways.”
DGBI, formerly known as functional gastrointestinal disorders, affect the way the gut functions without an identifiable structural or organic disease being found. Symptoms can include abdominal pain, changes in bowel habits and indigestion.
Internationally, the conditions are common. Research from the United Kingdom and Australia (who both have comparable publicly funded health systems) using contemporary diagnostic criteria, found that approximately 37 per cent of adults meet the criteria for at least one DGBI.
Using UK estimates of direct healthcare costs for IBS as a conservative proxy, they estimate that if one-third of New Zealand’s adult population has a DGBI, direct healthcare costs could be around NZ$1.6 billion a year.
Dr Bayer stresses that this is a modelled estimate, rather than a direct measurement of New Zealand’s current costs.
“However, even this conservative estimate points to a substantial burden. The important message is that we simply do not have the New Zealand data needed to understand the problem properly,” she explains.
The researchers found the evidence gap is particularly concerning for Māori, with no study identified measuring DGBI prevalence in Māori. They say future research should be designed from the outset to produce Māori-specific estimates and be undertaken in partnership with Māori health researchers and communities.
The paper also highlights the potential economic consequences of DGBI, which can involve repeated primary care visits, specialist referrals, investigations and medication, as well as lost productivity through absenteeism, reduced productivity at work and leaving the workforce early.
Dr Bayer says the findings demonstrate the need for dedicated research investment.
“We need to know how common these conditions really are in Aotearoa, how they affect different communities, and what they are costing patients and the health system,” she says.
“A national prevalence study, alongside a formal analysis of healthcare costs using New Zealand health data, would give us the evidence needed to improve diagnosis, treatment and planning.”
Publication:
Disorders of gut-brain interaction in Aotearoa New Zealand: a longstanding evidence gap with unmeasured health and economic consequences.
NZMJ November 20th 2026
Dr Simone Birgit Bayer (University of Otago, Department of Medicine, Christchurch)